Corpus Intelligence IC Memo — HARBOR-UCLA MEDICAL CENTER 2026-04-26 06:17 UTC
IC Memo — HARBOR-UCLA MEDICAL CENTER
Investment Committee Memorandum | CA | 369 beds | Grade B | EBITDA uplift $113.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HARBOR-UCLA MEDICAL CENTER

CCN 050376 | LOS ANGELES, CA | 369 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

HARBOR-UCLA MEDICAL CENTER is a 369-bed large academic medical center in LOS ANGELES, CA with $1.54B in net patient revenue and a -6.4% operating margin. The hospital serves a payer mix of 10.3% Medicare, 13.7% Medicaid, and 75.9% commercial.

Thesis: Undervalued. Our ML models identify $113.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.4% to 0.9% (+736bps).

Net Revenue HCRIS$1.54B
Current EBITDA COMPUTED$-99.1M
Operating Margin COMPUTED-6.4%
Occupancy HCRIS68.9%
Revenue / Bed COMPUTED$4.2M
Net-to-Gross HCRIS60.8%
Distress Probability ML45.4%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
153
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -6.4% places it below the state median. Among 153 size-comparable peers (184-738 beds), the median margin is -4.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (184-738), prioritizing same-state peers. 153 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HARBOR-UCLA MEDICAL CENTER (Target)CA369$1.54B-6.4%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $113.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$32.3M+210bp18mo
Cost to Collect4.5%2.5%$30.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$30.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$18.7M+122bp9mo
Clean Claim Rate88.0%96.0%$985K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$32.3M
Cost to Collect
$30.8M
Denial Rate Reduction
$30.5M
A/R Days Reduction
$18.7M
Clean Claim Rate
$985K
Total EBITDA Uplift$113.3M
Current EBITDA$-99.1M
+ RCM Uplift+$113.3M
Pro Forma EBITDA$14.2M
Current Margin-6.4%
Pro Forma Margin0.9%
WC Released (1x)$59.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-152.5M$479.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-152.5M$478.0M0.00x-100.0%
Bull Case9.0x11.0x$-137.3M$802.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-137.3M$835.0M0.00x-100.0%
Bear Case11.0x10.0x$-167.8M$-37.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-167.8M$-95.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 153 hospitals with 184-738 beds
  • Same-state prioritization (n=154)
  • Comp margins: P25=-15.8% / P50=-4.3% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.